洁特生物(688026) - 2025 Q1 - 季度业绩预告

Financial Performance - Estimated operating revenue for Q1 2025 is expected to be 123 million yuan, an increase of 24.72 million yuan or 25.16% year-on-year[3]. - Estimated net profit attributable to shareholders for Q1 2025 is expected to be 14 million yuan, an increase of 5.82 million yuan or 71.18% year-on-year[3]. - Estimated net profit attributable to shareholders after deducting non-recurring gains and losses for Q1 2025 is expected to be 13.5 million yuan, an increase of 9.26 million yuan or 218.52% year-on-year[3]. - The company achieved operating revenue of 98.28 million yuan in Q1 2024[4]. - The company achieved a net profit attributable to shareholders of 8.18 million yuan in Q1 2024[4]. Business Strategy - The company is focusing on R&D innovation, production processes, and refined management to enhance product performance and competitiveness[5][6]. - The life science products business continues to grow, with an increasing market share[6]. - The company is implementing cost reduction and efficiency improvement measures, along with smart upgrades to enhance production efficiency[6]. Legal Matters - There are ongoing significant litigation cases with a total amount involved of 39.65 million yuan, which may impact future profits[7]. Data Disclaimer - The data provided is preliminary and subject to final confirmation in the official Q1 2025 report[8].